Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study

Autor:	A, Sanyal, Z M, Younossi, N M, Bass, K D, Mullen, F, Poordad, R S, Brown, R P, Vemuru, M, Mazen Jamal, S, Huang, K, Merchant, E, Bortey, W P, Forbes
Rok vydání:	2011
Předmět:	Liver Cirrhosis Male Canada Middle Aged Rifamycins Severity of Illness Index Rifaximin United States Treatment Outcome Double-Blind Method Gastrointestinal Agents Hepatic Encephalopathy Surveys and Questionnaires Linear Models Quality of Life Humans Female Aged
Zdroj:	Alimentary pharmacologytherapeutics. 34(8)
ISSN:	1365-2036
Popis:	Hepatic encephalopathy (HE) is a brain disorder that often results from cirrhosis due to viral hepatitis, metabolic and alcohol-related liver disease, and is characterised by cognitive, psychiatric and motor impairments. Recurrent bouts of overt HE negatively impact daily functioning and quality of life.To evaluate the effect of rifaximin on health-related quality of life (HRQL) in cirrhotic patients with HE.Patients with cirrhosis in remission from HE (Conn score = 0 or 1) and a documented history of recurrent HE episodes (≥2 within 6 months of screening) were randomised to rifaximin 550 mg twice daily (N = 101) or placebo (N = 118) for 6 months. Concomitant lactulose was permitted during the study. The Chronic Liver Disease Questionnaire (CLDQ) was administered every 4 weeks, and time for occurrence of HE breakthrough was recorded. A longitudinal analysis using time-weighted averages of the CLDQ scores normalised by days on study therapy was used to evaluate the effect of treatment on HRQL, and between HE outcomes (HE recurrence, yes/no) irrespective of treatment.The time-weighted averages of the overall CLDQ score and each domain score were significantly higher in the rifaximin group vs. placebo (P-values ranged from 0.0087 to 0.0436); and were significantly lower in patients who experienced HE breakthrough compared to those who remained in remission (P-values were0.0001).Rifaximin significantly improved HRQL in patients with cirrhosis and recurrent hepatic encephalopathy. A lower HRQL may predict recurrence of hepatic encephalopathy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::1a8f9538cc82f883770632c5edc915a0 https://pubmed.ncbi.nlm.nih.gov/21848797 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.